Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies


Using our deep-rooted understanding of oncology discovery, we can add significant value to your project by expediting its progression through your discovery pipeline, from Target Validation through to Lead Optimisation and candidate nomination. Sygnature Discovery has an excellent track record of delivery in the oncology field, delivering 4 clinical candidates since 2011.

Our experienced scientists have developed a comprehensive discovery and translational oncology platform to allow efficient design, characterisation and development of your novel compounds using physiologically relevant systems.

Our broad oncology platform coupled with our extensive capabilities in Chemistry, DMPK, Computational Chemistry provide Sygnature with the necessary capabilities to support the most challenging oncology projects.

Our scientists work in close collaboration with you to generate flexible custom in vitro screening cascades, implementing state-of-the-art technologies and platforms across a variety of cell culture formats including 3D spheroids, scaffolds, primary cells and co-cultures.

Oncology Platform Highlights

We have a range of in vitro assays readily available to support your oncology programs, including:

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.


Diabetes is a metabolic disorder that is an increasingly prevalent disease worldwide. We have established assays to support the investigation of diabetic therapies including relevant functional assays. We also have access to tissue and blood from in vivo diabetic models through strategic collaborations.


Orphan Disease

Sygnature’s team of scientists have a strong track record of adding value to client projects in the field of rare and orphan diseases.  Sygnature’s advanced intellectual input and established relationships with providers of diseased tissue allows rapid progression of projects in this challenging therapeutic area.



Sygnature have a history of enabling discovery success in the field of anti-infectives. Our Medicinal Chemistry and Computational Chemistry teams have worked in close collaboration with many clients to design potent and efficacious compounds, resulting in the delivery of two preclinical candidates. Our Bioscience team can provide cytopathic effect and viability screening assays to assess compounds designed to inhibit virus attachment, entry or replication in human host cells.



Our scientists have a well-developed understanding of the challenges associated with the design and optimisation of compounds that target the central nervous system (CNS). Our experience is both broad, reaching across a number of neurodegenerative diseases (such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis) and neuropathic pain, and deep-rooted, with members of our senior team having 10+ years in CNS drug research.



We have an excellent track record of success in the field of respiratory diseases using our extensive in-house expertise, accelerating 5 compounds to the clinic and a further 4 into preclinical development for our clients. Our collaborative approach to drug discovery and our established network of KOLs in the field have been invaluable to the progression of our clients’ projects


Inflammation and Immunology

Our scientists have a rich heritage in this therapeutic area and provide significant experience in developing in vitro assays utilising Peripheral Blood Mononuclear Cells (PBMCs), T lymphocytes (e.g. CD4+/CD8+), leukocytes, and phagocytes, amongst others, that assess various inflammation and immunological biomarkers, processes, and endpoints.



Modulation of the immune system presents an exciting new approach for the therapeutic perturbation of cancer cell growth. Sygnature have developed a comprehensive platform to study the processes involved in immuno-oncology, including the assessment of cytokines, intracellular signalling, T-cell proliferation assays and antibody-dependent cell cytotoxicity (ADCC) assays.



We have successfully delivered more than 16 pre-clinical oncology projects, utilising our Integrated Drug Discovery expertise to develop small molecule drug candidates to treat a variety of cancers such as leukaemia, breast and prostate cancer. From initial screening and profiling through to clinically relevant Biomarkers, our DMPK and bioscience group can provide full support for your discovery projects.